Taiwan Liposome Company Ltd. (TLC)’s Financial Results Comparing With Ardelyx Inc. (NASDAQ:ARDX)

We will be contrasting the differences between Taiwan Liposome Company Ltd. (NASDAQ:TLC) and Ardelyx Inc. (NASDAQ:ARDX) as far as risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Taiwan Liposome Company Ltd. N/A 0.00 N/A -0.51 0.00
Ardelyx Inc. 44.52M 3.53 53.32M -0.96 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Taiwan Liposome Company Ltd. and Ardelyx Inc.

Profitability

Table 2 represents Taiwan Liposome Company Ltd. (NASDAQ:TLC) and Ardelyx Inc. (NASDAQ:ARDX)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Taiwan Liposome Company Ltd. 0.00% 0% 0%
Ardelyx Inc. -119.77% -37.2% -29%

Analyst Ratings

The Ratings and Recommendations for Taiwan Liposome Company Ltd. and Ardelyx Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Taiwan Liposome Company Ltd. 0 0 0 0.00
Ardelyx Inc. 0 0 1 3.00

Ardelyx Inc. on the other hand boasts of a $7 average target price and a 176.68% potential upside.

Insider & Institutional Ownership

Institutional investors owned 0% of Taiwan Liposome Company Ltd. shares and 85.2% of Ardelyx Inc. shares. On the other hand, insiders owned about 1.4% of Ardelyx Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Taiwan Liposome Company Ltd. 0.65% 0% 0% 0% 0% 3.62%
Ardelyx Inc. -10.29% -28.86% -35.79% -39.75% -58.99% -63.03%

For the past year Taiwan Liposome Company Ltd. had bullish trend while Ardelyx Inc. had bearish trend.

Summary

Taiwan Liposome Company Ltd. beats on 6 of the 10 factors Ardelyx Inc.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.